Clinical Trial Update: Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial evaluating universal CAR-T cells (REVO-UWD-00B) for refractory and relapsed multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Universal CAR-T Cells (REVO-UWD-00B) (CAR-T cell therapy)

Snippet

Sponsor: Wondercel Biotech (ShenZhen) | Conditions: Multiple Myleoma, Refractory and Relapsed Multiple Myeloma | EARLY_Phase 1 | Status: RECRUITING